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Dr Nicholas T. Kouchoukos (St Louis, Mo). I would like to
direct a few questions to the presenters and then open up the panel
to questions from the audience.
Dr Milewicz presented some fascinating data about the genetic
implications of many of these aortic diseases, and she also empha-
sized the importance of surveying first-degree relatives. This raises
the question of how we evaluate these patients. Obviously, imaging
is a very important way of doing this, yet we are seeing consider-
able criticism being leveled at some of the imaging techniques
we are using, principally computed tomographic (CT) scanning.
Dianna, can you tell us what the best way is to evaluate these
patients and what the safest way is?
DrDiannaM.Milewicz (Houston, Tex).We do not have a clear
answer for that. I think echocardiography is fine, particularly in
families in which you know the aneurysm is occurring in the
sinuses of Valsalva. I think it may be okay for ascending lesions
if on the echocardiogram you get good imaging of the ascending
aorta. If you do not, then you do have to go to CT scanning or mag-
netic resonance angiography.
DrKouchoukos. If you are not going to do an echocardiogram, if
you are going to use another type of imaging, what about the issue of
radiation exposure in patients who have to have sequential studies?
Dr Milewicz. That is a problem and I do not have an answer
for that, other than you can use magnetic resonance angiography
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The Journal of Thoracic and CarDrKouchoukos.Dr Elefteriades presented some very good data
that he has been accumulating over a number of years regarding the
natural history of aortic aneurysms and the size limits for recom-
mending surgery. John, you did not mention anything about the
difference between patients with chronic dissection and patients
with degenerative aneurysms of the descending thoracic aorta.
Are the numbers equivalent? Should we be operating on smaller-
diameter dissected aortas?
Dr John Elefteriades (New Haven, Conn). I do not have any
data on that. The data that we have are similar to what has been
shown by others: that the natural history is abysmal once the dissec-
tion has occurred. The survival curve is much lower.We have never
separated out our chronic dissections from our degenerative aneu-
rysms because the numbers are relatively small.
Dr Kouchoukos. I recall that Dr Griepp’s group has shown that
perhaps the risk of rupture is a little bit higher in patients with
chronic dissection as compared with those with degenerative dis-
ease. Should we operate earlier than 6.5 cm in the descending aorta
and 5.5 cm in the ascending aorta in patients who have chronic
dissection in the absence of Marfan syndrome?
Dr Thoralf M. Sundt (Rochester, Minn). My practice is to be
more aggressive in patients with a dissection, but I do not have
data to support it.
Dr Kouchoukos. Do you have any numbers that you use for an
aneurysm of the descending aorta, or a chronic dissection, as to
when you would consider open—not endovascular—intervention?
Dr Sundt. For intervention in a chronic dissection, I would drop
the criterion by about a centimeter. The other factor I would con-
sider is the age of the patient. Craig Miller has talked about this:
what you do with the young patient with severe hypertension
whom you just believe is going to be a bad actor. I oftentimes bring
such patients back much more quickly for a follow-up scan. Fre-
quently, they demonstrate remarkable enlargement. Therefore, I
think there is an age effect as well, and we probably should be
more aggressive in younger patients.
Dr Kouchoukos. Let’s move on to the valve-sparing proce-
dures. Dr David showed us his results with his David V procedure
and also indicated that he had done a fair number of procedures
with a straight tube graft. Is there really any difference in the
long-term outcomes between the two in your experience?
Dr Tirone E. David (Toronto, Ontario, Canada). It is an unfair
comparison, because until about 1998 I had done only straight
tubes. Therefore, the longest follow-up is with a straight graft.
We have the lowest incidence of reoperation in that group. We
started tailoring the grafts, and at the same time we started tailoringdiovascular Surgery c Volume 140, Number 6S S45
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condition. That is why all these retrospective reviews are difficult to
use in weighing one technique against another. The answer is that in
our hands a straight tube or a tube with a Valsalva has not yet made
a difference after 20 years of experience.
Dr Kouchoukos. Dr De Paulis showed some data that the
outcomes were better in the patients who were operated on with
1þ aortic regurgitation in comparison with those who had greater
degrees of regurgitation. Has that been true in your experience as
well?
Dr David. No, not at all. Cusp repair has no effect on late out-
come. However, there is an intrinsic bias there. As the surgeon, it
is my inspection that determines what is a good cusp or a bad
cusp. To have all 3 cusps damaged is not uncommon. If you are
at a referral center, you are getting younger and younger patients
who come to you to have a valve-sparing procedure, not to have
a Bentall procedure. So we repair the valves, and thus far, cusp re-
pair has not increased the risk of a bad outcome. I think Joachim has
had the same experience, and Gebrine, whom I trained, has had the
same experience: cusp repair does not increase aortic insufficiency.
Dr Ruggero De Paulis (Rome, Italy). There are two different
situations with regard to cusp prolapse: sometimes cusp prolapse
is unrecognized by the surgeon, but sometimes it can be induced
by the procedure, especially because the patient’s geometry is being
altered, at least a little bit. That is why we may have some differ-
ences in results. I do not think we can do anything about this. It
is difficult to judge which procedure is best if you start with a differ-
ent patient.
Of course, the best way to judge two different procedures is to
start with a perfect leaflet. Early in the process of dilatation of the
root, we can probably find a good leaflet. I think if you want to
increase the chance of having a perfect reconstruction, you should
operate a little before you get significant aortic insufficiency, even
though it is difficult to find a relationship between the degree of
preoperative aortic insufficiency and the optimal result of the oper-
ation: often this is because the surgeon used other maneuvers in
addition to simple root reimplantation.
Dr Kouchoukos. We have been presented with superb results
from all of the surgeons who have discussed the valve-sparing pro-
cedures: extremely low mortality rates and extremely low reopera-
tion rates. Excluding patients with Marfan syndrome, does this
mean that we should be repairing these valves at an earlier time,
even in the absence of any aortic regurgitation? If so, where do
we draw the line?
Dr Hans-Joachim Schaefers (Homburg/Saar, Germany). I
have a somewhat different belief. I like Thor’s presentation of the
denominator problem. The tool we have is effective but not harm-
less. If we lower the threshold for operation, we will include many
patients who currently are being treated conservatively, and at this
time we have no calculations as to whether we are actually doing
something good or whether, looking at the whole population, we
are creating more harm than good. I think we will really have to
carefully consider that possibility. I am often confronted with that
question by referring cardiologists, who point out that we can repair
the valve, and then ask whether we should proceed along lines sim-
ilar to what we do with the mitral valve, where the severity of mitral
regurgitation is sufficient indication for surgery in guidelines both
here on this continent and in Europe. However, with the mitralS46 The Journal of Thoracic and Cardiovascular Surgvalve, we have a track record of 30 years. In aortic valve repair,
especially when the cusp aspect is involved, we are looking at
10 or 15 years, and I think it is simply too early to become more
aggressive.
Dr David. I think if the patient needs an operation, the operation
should be done. But first you must find out who needs an operation.
The natural history, as correctly presented by both John and Thor, is
not that bad. The progression is steady. Size does not matter any-
more. Half the dissections occur in patients with a normal-sized
aorta. So are you going to go out and replace every aorta? I think
the traditional indications for surgery should prevail.
Dr Kouchoukos. Thor, you raised some important and contro-
versial issues that are relevant to the present discussion.What about
a patient who has a bicuspid valve that is functioning normally and
has a dilated ascending aorta? When do you make a recommenda-
tion to replace that aorta?
Dr Sundt. I have a 50:50 rule: if the aorta is 50 mm and the pa-
tient is 50 years of age, I throw up my hands and advocate replacing
the aorta. But much lower than 50 mm, I am hard-pressed to find an
argument to replace that aorta.
I think that Tirone is right. The problem is that size is not a good
predictor. We need the genetics. There are two sides of this equa-
tion. Dissection is a structural failure of the aorta, and it is related
to the mechanical stresses and the material properties of the aorta.
The stresses on the aorta are determined by the diameter and by the
blood pressure. We know that patients with hypertension are at
greater risk, and we can control their blood pressure.
Then there is the issue of the material properties, so smoking is
a bad idea. We are given some clues by the genetics about the ma-
terial properties. Patients with Marfan syndrome, for example, have
abnormal material properties and thus they are at a higher risk of
structural failure. However, until we have a more sophisticated as-
sessment of what those material properties are, we are stuck.
DrMilewicz. I want to mention that although we started our ge-
netic studies focusing on gene mutations that were similar to Mar-
fan syndrome, more recently we have looked for genetic alterations
that are there in the population but predict ascending aneurysms and
dissection. We will be coming out with some of those variants over
the next year, and that may help us in guiding determination and
timing of surgery both for patients with bicuspid aortic valves
and for those without.
Dr Kouchoukos. The genetic testing you mentioned is expen-
sive and not readily available. How is that going to change in the
future?
DrMilewicz.Genetic testing is actually readily available. If you
go to the GeneTests Web site (http://www.ncbi.nlm.nih.gov/sites/
GeneTests), you will find a list of commercial laboratories that
test any of the genes that I talked about except for the kinase
gene that we found just recently. And the cost is falling rapidly.
Sequencing technologies are improving almost on a monthly
basis, and I think that the cost of these tests will continue to drop.
Dr Kouchoukos.What about insurance coverage of these tests?
Dr Milewicz. That is another question. I think this is something
that we have to push as we identify more genes: to make sure that all
insurance covers genetic testing. About half the policies do cur-
rently: we can push the insurance companies and get another quar-
ter to pay.
Dr Kouchoukos. Let’s open up the discussion for questions.ery c December 2010
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Dietz syndrome, what extent of the operation we should perform?
Do you replace the arch or not? You talked a little about the
approach being the same, but how much aorta should we replace?
Dr Duke E. Cameron (Baltimore, Md). We do not know the
answer to that. That is a discussion that is ongoing. Until now,
we have just replaced the ascending aorta up to the crossclamp.
We do not do a hemiarch, and we do not routinely use circulatory
arrest. However, it is our impression that we are seeing many more
Loeys–Dietz patients come back with dilated arches than we have
seen with Marfan syndrome. That is a question that we will have to
answer, but we have not changed our practice yet.
Dr A. Trento (Los Angeles, Calif). I am following a fair number
of patients with bicuspid valve—with a normally functioning valve
and a dilated aorta—and I see that the aorta really does not increase
in size: they have an aorta of 4.5 or 4.7 cm, and it stays at that level.
Obviously, this is a small number, but I have the impression that
medical therapy in these patients will go a long way. What is
your impression?
Dr Sundt. You can tell from my presentation that I agree with
you, but John has some data about it.
Dr Elefteriades. Yes, this is an indolent disease, not only for
those with bicuspid valves, but also for those with other ascending
aortic aneurysms. The rate of growth is very low, 1 mm per year,
and I think your observation is right on the money. Those patients
will eventually grow if you look at them over 5 to 10 years. We
cannot really detect growth until 3 or 4 years have gone by, because
we cannot measure 1 mm at a time.
Dr David. I have never looked at this prospectively in my
practice, but I have the impression that an aorta of 47 mm in
a 20-year-old patient does not behave the same as a 47-mm aorta
in a 50-year-old patient. In the younger patients the aorta dilates
more along your rate, 0.1 to 0.2 cm per year. In the older ones,
the aorta does not. It seems to be more stable. Don’t you think
age is a factor?
Dr Elefteriades. We know that the aorta grows a little bit with
age, even if it is normal. We have not ever identified a slowing of
growth with advancing age, but we could look at that: it would be
easy to look at.
Dr Sundt. It makes good sense that if the aorta is already 48 mm
at 25 years of age, the material properties are abnormal.
DrMilewicz. Therefore, the younger the patient, the more likely
there is an underlying genetic variance.
DrDavid. It accelerates the disease of a patient. I do not think all
dilatations are the same.
Dr T. Beaver (Gainesville, Fla).Wonderful data from Dr Mile-
wicz. I waswonderingwhether she had any screening recommenda-
tions. I would appreciate it if Dr Elefteriades orDr Sundt or someone
else from theUnited States could tell us what their current practice is
if someone comes inwith an aortic dissection.Do you start talking to
the family and recommending CT scans for siblings?
Dr Milewicz. Definitely, if there is a family history, we recom-
mend screening. As I mentioned previously, an echocardiogram
may be sufficient in many of the cases. For patients without a family
history, we would certainly recommend screening if they are
young, starting with the parents. If both of the parents are normal,
we are less worried about the siblings having aortic disease. For the
older patients, we really just do not know.The Journal of Thoracic and CarDr Kouchoukos. What about patients with bicuspid aortic
valves?Do you recommend screening of their first-degree relatives?
Dr Milewicz. Inasmuch as that can run in families, we certainly
recommend screening if there is a history of aortic dissections. The
studies have shown that those families can have aortic disease with
bicuspid aortic valve, bicuspid aortic valve without aortic disease,
or aortic disease and no bicuspid aortic valve. So you definitely
screen if there is a family history and also if the patient is young.
Dr J. Greelish (Nashville, Tenn). There was a review a few
years ago in Nature Clinical Practice by Drs Sundt and Davies
that looked at the morphology of aortic dilation in bicuspid valve
disease and described various types: the root may dilate, the as-
cending aorta may dilate, or an intermediate form may exist.
When making the decision to do aortic replacement in a patient
with bicuspid valve, is it always necessary to perform a root oper-
ation, or is a supracoronary graft sufficient?
Dr Schaefers. I think this is a very good question, but as Dr
Sundt implied, at this time we have absolutely no data. Because
of the scarcity of data and the fact that many of these roots remain
stable over time, I think it is safe simply to leave the root as it is and
just replace the supracoronary ascending aorta. The important
question—the final question on my conclusion slide—is this: at
what diameter should we go ahead and replace the root? At this
time we have some indirect evidence that the 45 mm that came
from the Toronto group may also be reasonable, but this is a gut
feeling. It is evidence level C that 45 mm may be reasonable, but
we have absolutely no calculations, no numbers.
Dr De Paulis. What do you do in the case in which one sinus
takes up most of the diameter of the root? Often with a bicuspid
valve, you have two sinuses that are smaller and one that is bigger.
This is a different situation. Probably you have to replace that sinus.
Dr Schaefers. It is a different situation whatever you do,
whether you replace one sinus or whether you do a whole root
replacement. Again, we have no evidence; we have no numbers.
All we know is that the Laplace law is applicable also to the root,
and the Laplace law does not really take into consideration that
one sinus is abnormally large. There is some indirect evidence if
we look at the patch plasty of coarctation, the old approach of put-
ting a Dacron patch in the area of the coarctation. This proved to be
not so good in the long term, because many of these patients had
aneurysms develop. Maybe it is not such a good idea to have an
asymmetric operation, to have plastic on one side of a root and
natural aortic tissue on the other. But, again, the evidence level is
maybe D: very weak.
Dr Gebrine El Khoury (Bruxelles, Belgium). For bicuspid aor-
tic valve there is also the diameter of the sinus to consider. Even if
the diameter is acceptable, we have to assess the quality of the aortic
wall, and in many patients with normal aortic root diameter, we can
see that there is no longer anywall in some areas: it has disappeared;
the aortic wall is very thin. In such a patient, in my experience,
I replace the aortic root.
The second comment is that if you are operating on a regurgitant
bicuspid aortic valve, I think one of the elements required to stabi-
lize the aortic repair and to have long-term durability is to do some-
thing with the aortoventricular junction and the sinotubular
junction. If I am repairing a regurgitant bicuspid aortic valve in
a young patient, even if the aortic root is quite normal, I will do
valve-sparing surgery and repair the aortic valve.diovascular Surgery c Volume 140, Number 6S S47
Aortic Symposium 2010 Discussions: Session I and Session IIDr Sundt. Those patients with aortic regurgitation most often
have a phenotype that demonstrates enlargement of the sinuses.
One of the things that needs to be mentioned is that when you
talk about doing a root replacement in someone with normal-
sized sinuses, they have undisplaced coronary arteries. It is techni-
cally harder, at least it is for me, to mobilize those coronary buttons
and reimplant them. So the other side of the risk equation goes up. I
think the risk of replacing a normal root is higher than the risk as-
sociated with replacing a dilated root.
Dr Emmanuel Lansac (Suresnes, France). I have just a quick
comment on the size of the root for graft placement. In our practice,
when the root is below 40 mm, we will leave the root, and if there
is an indication for only the root, we go for 50 mm. If the indication
is for the valve with a root above 40 mm—and most of the time if it
is 45 mm—we will replace it. If it is a young patient and if the cor-
onary ostia are high—when the root is above 40 mm—I think it is
good to replace it and treat, as Gebrine El Khoury said, the annular
base dilatation at the same time.
Dr C. Van Doorn (Aarhus, Denmark). As Dr Cameron showed
very convincingly for the patients with Marfan syndrome, and as
was also shown by the other speakers, the remaining native aorta
is the major source of mortality and morbidity at follow-up. Could
the panel please comment on blood pressure management after sur-
gery, such as the use of beta-blockers and angiotensin-converting
enzyme inhibitors, and also, in particular, the use of losartan?
Dr Cameron. I would venture that most people on this panel are
probably not involved in the long-term management of blood pres-
sure. The short answer is that I think we try to maintain aggressive
control of the blood pressure, certainly keeping systolic less than
120 mm Hg and pushing beta-blockers to the point that they are
just tolerated. Increasingly in our institution, I think because of
the interest in losartan and the way it addresses what we think is
the pathogenesis of some of these aneurysms, virtually all of our
patients are receiving losartan as well as a beta-blocker.
Dr Kouchoukos. Duke, do you have any data about the benefits
of the treatment in the losartan group?
Dr Cameron. No.
Dr Milewicz. The interim analysis for the losartan trial in chil-
dren with Marfan syndrome up to the age of 25 years should be
available within the next 6 months, so we will know whether the
trial continues or not.
Dr M. Janusz (Vancouver, British Columbia, Canada). If you
have a patient with mild to moderate aortic stenosis and a 51-mm
ascending aorta, the valve, if left alone, would not represent
much of a hazard to the patient for several years, but no one is going
to leave it behind. Are they better to have a prosthesis for several
extra years or to be followed up with an aorta that is bigger than
the recommended guidelines?
Dr Sundt. How old is the patient?
Dr Janusz. Let’s say 50 or 60.
Dr Sundt. The older the patient is, the closer you are to being in
the clear for one of the options being a bioprosthetic valve with
a low risk of reoperation. So the older the patient is, the more easily
one could argue for a lower threshold for surgery. Why take the risk
of dissection when you have a good chance that a bioprosthetic
valve will be durable? It is tougher in a patient who is 50.
Dr Janusz. It is not just a question of durability; it is the annual
risk of endocarditis and thromboembolism. In that size range, 50 toS48 The Journal of Thoracic and Cardiovascular Surg55 mm, is the hazard of carrying the valve greater than the annual
risk of dissection? I have not seen any data on that.
Dr Schaefers. I am not aware of any published data. I see your
dilemma, and I would feel the same. In case of doubt I would prob-
ably remember what Thor Sundt pointed out: we are not 100% cer-
tain whether a 51-mm ascending aorta in the presence of a bicuspid
valve is all that deadly. I would prefer to monitor the patient care-
fully, making sure he or she has good blood pressure control and so
forth.
The guidelines actually open a rational window, in cases of mod-
erate aortic stenosis, for looking at the degree of calcification. If cal-
cification is very severe, the likelihood of that patient needing valve
surgery within the next couple of years is very high, which would
then give you a possible rationale for earlier surgery. I think this
decision—in the absence of good data for this specific situation—
has to be individualized.
Dr Kouchoukos. Thor alluded to this problem: we have all seen
patients who have had an aneurysm that is discovered on an inci-
dental CT examination. Body scans that were popular a few years
ago uncovered a lot of patients who had aneurysms. Some of these
patients arrive in your office totally terrified either by their own
reading on the Internet or by what they have been told by their
physicians. Some of them demand to have their aortas removed.
How do we deal with this dilemma?
Dr Sundt. I think we need to quit scaring people to death: that is
part of my plea. The woman that I discussed with you was seen by
Heidi Connolly, one of our cardiologists who specializes in cardio-
vascular disease in women in pregnancy. Heidi recommended that
she could have a pregnancy with careful control of her blood pres-
sure; I said that she could have a pregnancy. However, she was so
terrified by what she had been told before that she went home and
had a composite root replacement and had her tubes tied. I think that
is a tragedy. Once the seed has been planted that someone has
a time bomb ticking in her chest, it is very hard to reassure her. I
think that we need to be responsible about what we tell the public.
Dr R. Calhoun (Sacramento, Calif). Moving to a slightly less
elective scenario, I am curious about the panel’s philosophy in
patients who have a type A dissection, but type A in the sense
that theymay have a pericardial effusion. They may have early tam-
ponade. They need something urgently done. However, the tear
itself is in the arch or perhaps even distal to the subclavian. What
is the philosophy? Are we there simply to deal with the ascending
aorta and save the patient’s life, or should people be chasing these
tears even if it means doing a complex arch reconstruction at 3 in
the morning?
Dr Schaefers. I do not think there is a quick and simple answer
to this difficult question. I would suggest discussing this after the
arch session.
Dr Kouchoukos. I think we will leave it for later.
DrH. Sherif (Newark, Del). In cases of bicuspid aortic valve, the
dilatation in the ascending aorta is often eccentric at the greater cur-
vature. It is not the usual fusiform shape of many other aneurysms.
What do you think about segmental patterns of aortic dilatation in
specific disease entities and how they affect management of that
particular situation?
Dr Schaefers.We know that we do not know. It is a very good
thought. Actually, over the past 1½ years, we have selected samples
of different areas of the ascending aortic wall to look into thatery c December 2010
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hemodynamics, of turbulence directed toward the outer curvature,
or whether there is a regionalized specific phenomenon in the aortic
wall. So far, all the information we have is global and does not dif-
ferentiate specific areas of the aortic wall. I think there is no good
answer to your question, but it is a good question.
Dr Kouchoukos. I believe there was an abstract presented at the
American Heart Association meeting describing histochemical
analyses in different parts of the ascending aorta. The authors did
identify differences between the greater curvature and the lesser
curvature. Dianna, do you have any thoughts about that?
Dr Milewicz.My argument would be that there would be more
changes with the hemodynamic stresses on one side of the aorta,
which is what you would expect to see, rather than that the response
is an attempt to repair what the wall is sensing is a vascular injury.
Dr C. Miller (Stanford, Calif). I am delighted by the blunt hon-
esty of this panel. Maybe as we all get older, we get a little more
mature and wise, but I have never heard so many distinguished
experts say ‘‘I don’t know.’’ I really applaud all of you.
Duke, did I hear you say that Hal Dietz has convinced you to
push the beta-blockers to the point of tolerance in addition to losar-
tan in the bicuspid valve patients?
Dr Cameron. I do not think I said that, but I think that is his
practice.
Dr Miller. Does he perhaps think it is the same disease even
though it does not involve fibrillin-1 or transforming growth factor
beta perhaps?
Dr Cameron. I am sure he would not say it is the same disease,
but I think he believes there is a lot of overlap.
Dr Miller. Dianna?
Dr Milewicz. We do not know.
Dr Miller. I love that. We were talking about replacing a valve
and leaving some generous sinuses, or Gerbine says we are saving
a leaking bicuspid valve in a young patient and the sinuses are not
that big. I agree with Gerbine 100%. It is very uncommon not to
have annular dilatation be an important component of the mecha-
nism of leak in any type of bicuspid aortic valve, whether it be Si-
evers 0 or Sievers 1, and if you do not address the annular dilatation,
you are probably not going to have a very durable valve repair. One
of the panelists also said to look at the quality of the wall of the
aortic root: that was Gerbine, too. Who cares what size it is if it
is transparent? You had better replace those sinuses even if it is
a Fazel cluster II aortopathy in which the sinuses are of relatively
normal size.
Dr J. Bachet (Abu Dhabi, United Arab Emirates). I would like
to ask a very simple question of the experts of the valve-sparing
procedure here on the panel. They gave us a lot of data, but there
is one figure that I never find in the papers or presentations. How
many patients, in their experience, go into the operating theater
with the intention of having a valve-sparing procedure and come
out with a valve? In my small experience of 75 aortic valve–sparing
procedures, there were, in addition, 5 patients in whom I tried to
preserve the valve, but I had to replace it because my result was
poor. These data are never provided. It would be interesting to
know the rate of intraoperative failures in the experts’ experience.
Dr Kouchoukos. That is an excellent question.
Dr Cameron.We have written on that. I think I actually said at
this meeting a couple of times that about 10% and in some yearsThe Journal of Thoracic and Caralmost 20% of the patients who come to the operating room for
a valve-sparing procedure leave with a more traditional composite
graft. You can set your threshold wherever you want as to what you
think is a salvageable valve, and a lot of it has to do with the age
of the patient. We will bend over backward to save the valve of
a 10-year-old child, but in a 70-year-old patient with a lot of fenes-
trations who comes with a fair amount of aortic insufficiency to
start with, we are not going to work as hard. It will also depend
on the nature of your referral practice. We have a lot of very young
patients, but even with that, 10% to 20% will have the valve
replaced. We will take into consideration age, the number of fenes-
trations, and the amount of aortic regurgitation preoperatively.
Dr De Paulis. I think it would be around 20% before actually
looking at the valve intraoperatively and about 10% after looking
at the valve. This is especially likely in those cases in which, even
after looking at the valve, you know you should not do it, but you
give it a try because the patient is motivated.
DrDavid. I am the oddball here. My figure is close to 0%. How-
ever, I do not take any patient before seeing a transesophageal echo-
cardiogram. As with mitral valve repair, I do not replace a mitral
valve that I take on to repair. If I tell the patient I am going to repair
it, it is because the transesophageal echocardiogram showed me
that the leaflets are reparable. Aortic valve sparing is the same
thing. If you have no leaflets, do not try to repair or you end up
with more pericardial patches than native tissue. Transesophageal
echocardiography is the gold standard in my experience to deter-
mine whether the aortic valve is salvageable or not. To be quite
honest, in the past 10 years I do not remember one patient accepted
for valve sparing who went home with a Bentall procedure, except
perhaps in bicuspid aortic valve. I told the patient that one cusp did
not look too good and that he might end up with a Bentall proce-
dure. But with a tricuspid aortic valve, the rate is very close to 0%.
De El Khoury. I agree completely. There are two determinants
for reparability of the valve. The first is the quality of the leaflets,
and it will be very well assessed by the echocardiogram: 3-dimen-
sional, transesophageal, or whatever. The second factor is how
aggressive or experienced is the cardiac surgeon. In my experience,
I can tell you that this patient, when he comes to the operating room,
has a 100% chance to have the valve repaired or 100% likelihood
to have it be replaced. It is really very easy now to assess the repar-
ability of the aortic valve or the feasibility of valve-sparing surgery
provided we have a good assessment of the quality of the leaflets
beforehand.
Dr Kouchoukos. Tirone, what on the echocardiogram tells you
that you are not going to be able to repair the valve?
Dr David. If the leaflets are calcified, if the free margin is rolled
in, and if it is very echogenic. If all 3 leaflets are very echogenic at
the free margin, I tell the patient a repair will be inadequate. If the
height of the leaflet (you measure the height when the leaflet is
open) is 10 mm, it is reparable, but we are not offering a repair.
That is perhaps why my results are so good. I am cherry-picking.
I am repairing those that can be repaired and trashing those in
which repair might be marginal. We consider the height of the
leaflet, how echogenic the leaflets are, and their thickness. A com-
missural regurgitation in our hands almost invariably means fenes-
tration, but fenestration, as I mentioned earlier, can be repaired with
polytetrafluoroethylene (Gore-Tex; W. L. Gore & Associates, Inc,
Flagstaff, Ariz).diovascular Surgery c Volume 140, Number 6S S49
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Dr David. Some cannot, but if there is massive regurgitation
through a commissural area, it is no longer a fenestration. The leaf-
let has become detached. In those cases, I do not tell the patient I am
going to repair. Once I accept a patient with a transesophageal
echocardiogram, I think that happens rarely; I only remember
one instance in the past decade. However, I tell many patients
that they should not have a repair: a Bentall procedure with valve
sparing is a bad operation if the echocardiogram showed severely
damaged cusps.
Dr Lansac. Yes. Thank you, Jean, for your question. Interest-
ingly, there are 2 points. There are candidates for valve sparing
who will not have it in the operating room, and actually, in my
experience, it is more likely elderly patients with fenestrations.
However, I think it is also interesting to know how many patients
come to the operating room to have a valve-sparing procedure
and then are converted.
Dr Bachet. That was my question.
Dr Lansac. That is the way I understood it, and that was inter-
esting. We started a review of the literature and of our initial expe-
rience with the isolated remodeling technique, and we had a 30%
failure rate in the operating room: remodeling cases that were con-
verted to aortic valve replacement. From that point came the idea of
combining the remodeling technique with a subvalvular annulo-
plasty. In the review that I presented to you, of more than 187 pa-
tients, the rate of conversion using remodeling alone dropped to
less than 3% when we carried out the annuloplasty. What will re-
duce even further the rate of conversion in the operating room—and
I agree that this should be published in every report—is the stan-
dardized management of the cusp, especially using the effective
height concept developed by Joachim Schaefers. This concept
may help increase the reproducibility of the technique and help
reduce failure in the operating room.
Dr Bachet. Tirone and Gebrine say that they never had a techni-
cal failure. Do you mind if I remain a little skeptical?
Dr David. No, I did not say that. I said that in the past decade,
patients whom I said would have their aortic valve repaired had
the repair. If you read all my articles, I am very open in saying
that my very first reimplantation worked well, and that the second
one failed in the operating room, and on the second day, the valve
came out. This is a different story. You asked me, if you look at
a valve, can you say whether it can be repaired or not? I consider
myself expert enough to say. And so far in the past 200 cases, I
have not let the patient down. So it is possible to detect a patient
suitable for valve sparing before surgery.
Dr Schaefers. I would agree that valve sparing can be done in
95% or so. I do not want to go into a big philosophical discussion
but rather to volunteer a couple of numbers. Intraoperative conver-
sion after a failed repair is 1%.
Intraoperative conversion after trying a repair that does not look
so good—going for replacement rather than testing the valve by
transesophageal echocardiography—is in the range of 2%. In pa-
tients in whom I find a valve that will not last very long, considering
patient age and so forth, replacement is probably somewhere in the
range of 5% to 10%.
Dr El Khoury. In the beginning of my experience, I had to re-
pair the valve again in 5% to 7%, but now we are really close to
0%. We can achieve an immediate repair; it is predictable. NowS50 The Journal of Thoracic and Cardiovascular Surgthe discussion is about durability, and I agree that this is something
else. But for the immediate achievement of a successful repair, I
think we can accept a 98% to 99% reparability rate.
Dr Lansac. I agree that with experience the rate of conversion is
getting lower, but the main problem is the lack of standardization of
the technique. To further lower the rate of failure, we think it is very
important to standardize this complex operation, breaking it down
into very simple steps and standardizing every step in root and cusp
management. The majority of us will not treat a lot of these patients:
between 2 and 5 patients per year. Even if there are experienced
centers that are very good, most patients, in real life, are operated
on in the hospital nearest their home. So we need to have strict
criteria to manage the root and to deal with the technique to have
reproducible results in the operating room and to reduce the failure
rate. The lack of standardization is the main limitation to the
widespread use of the valve-sparing procedure.
Dr M. Misfeld (Leipzig, Germany). I would like to know the
panel’s opinion regarding indications for performing an aorto-
plasty. Is there still any indication to do this and, if so, up to what
size? Replacement of the ascending aorta increases the wall stress
on the residual aorta, which may have an impact on its development
of aneurysms.
Dr Elefteriades. Francis Robicsek is the remaining proponent
of aortoplasty, and he wrote a nice article on that which came out
about 5 years ago showing good results. I think most of the world
has left that behind, because the added work of doing an aortic
replacement is really very little beyond the work that would be
required for an aortoplasty. In my own practice, I do it on rare
occasions, but I reserve it for somebody who is perhaps very old,
needs a ton of grafts, needs a valve, and we just want to do some-
thing to minimize the likelihood of an aortic event in the next few
years.
Dr Kouchoukos. Do you wrap it, John, or are you comfortable
just reducing the diameter?
Dr Elefteriades.We are comfortable just reducing the diameter.
I worry about a wrap that does not go down to include the annulus
the way the Florida sleeve does, because I think there is a lot of
tension at the edge of that wrap.
Dr B. Koul (Lund, Sweden). I would like to take up the question
of Dr Jean Bachet and extend it further. Drs El Khoury and Schae-
fers have taught us that when the coaptation height is less than 4
mm, or the line of coaptation is near the annulus or subannular,
the long-term failures are high. We saw today from Dr Schaefers’
presentation that he is now more and more aggressive about raising
the coaptation height to reach 8 or 10 mm. How has this affected
your repair success rate? Are you ending up with good coaptation
but with cusps that do not meet in the center? How does it affect the
intraoperative success rate?
Dr El Khoury. There is a difference between the optimal height
and what we have. For the optimal height, in the normal aortic
valve, the leaflet should be at the mid height of the sinuses. We
found in our study that if the coaptation is at more than 4 or 5
mm, the durability is acceptable. But I think the durability can be
perfect if we achieve excellent coaptation. This gives me the
occasion to make one comment. When operating on patients with
a normally functioning aortic valve and with a root aneurysm, I
think if your surgical techniques give you the same geometry of
the valve without adding any leaflet maneuvers, you have anery c December 2010
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heard that intervention on the leaflet is more and more frequent.
I think it is because we have not yet found the optimal, appropriate
surgical technique. If I go from a normally functioning and nor-
mally configured aortic valve and root annulus, I end up with a nor-
mal configuration of the aortic leaflet without any intervention on
the leaflet. This gives the impression or the feeling that one must
have gotten the surgical technique exactly right. The second com-
ment is that the level of coaptation is crucial for the durability of the
aortic valve repair.
Dr Schaefers.A scientific answer: in a receiver operating charac-
teristic analysis, an effective height of more than 8 or maybe 9 mmThe Journal of Thoracic and Carwas a positive predictor of durability. This referred to the bicuspid
valves, which we have studied best. Second, mentally, for me,
measuring something—rather than eyeballing, questioning myself,
reconsidering, and so forth—makes this operation more reproduc-
ible. Thor brought up an interesting question just after youmentioned
yours. Can you bring the cusp up too high? Yes. If you shorten it too
much, you will make it restrictive and you will induce restrictive
aortic regurgitation. At this point, we have a tool that we can use,
whereas before we had no tool. It is not ideal yet, but it allows us
to guide the operation in a halfway predictable fashion.
Dr Kouchoukos. I thank all of the panelists for their excellent
presentations and for the discussion.diovascular Surgery c Volume 140, Number 6S S51
